Drugs.com New Drug Approvals · 8/28/2026
FDA Approves Lilly's Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
INDIANAPOLIS, August 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of...
Why this is tracked
This item matched GLP-1, Medicare, Part D, CMS, FDA, coverage, pricing, prior authorization, or access terms used by the daily monitor.
Read the source
This page summarizes and links to the original source. Use the source article, CMS/FDA notices, plan documents, and clinician guidance for decisions.